Not applicableStudy completedNCT06359067What this trial is testingA Real-World Study of Bispecific Antibodies in Multiple MyelomaWho this might be right forMultiple Myeloma Assistance Publique - Hôpitaux de Paris 600
Not applicableStudy completedNCT05565391What this trial is testingLearn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Pfizer 508
Testing effectiveness (Phase 2)Looking for participantsNCT07382739What this trial is testingRadiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"Who this might be right forPhase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649359What this trial is testingMagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbWho this might be right forMultiple Myeloma Pfizer 187
Testing effectiveness (Phase 2)Looking for participantsNCT06974786What this trial is testingFrontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaWho this might be right forMultiple Myeloma, Newly DiagnosedMultiple Myeloma (MM) SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Looking for participantsNCT06920251What this trial is testingPhase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapyWho this might be right forRelapsed Refractory Multiple Myeloma (RRMM) Seoul National University Hospital 40
Not applicableStudy completedNCT06592222What this trial is testingLearn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesWho this might be right forMultiple Myeloma Pfizer 4
Testing effectiveness (Phase 2)Looking for participantsNCT06711705What this trial is testingElranatamab in Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma University of California, San Diego 33
Testing effectiveness (Phase 2)Looking for participantsNCT06988488What this trial is testingDetermine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Celgene 62
Not applicableNo Longer AvailableNCT05238311What this trial is testingPre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Who this might be right forMultiple Myeloma Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06569147What this trial is testingElranatamab in Patients With Relapsed or Refractory AL AmyloidosisWho this might be right forAL Amyloidosis Brigham and Women's Hospital 49
Testing effectiveness (Phase 2)Looking for participantsNCT06645678What this trial is testingMezigdomide and Elranatamab for Relapsed and/or Refractory Multiple MyelomaWho this might be right forRelapsed Refractory Multiple Myeloma (RRMM) YOUNGIL KOH 75
Testing effectiveness (Phase 2)Looking for participantsNCT06138275What this trial is testingElranatamab in R/R Multiple MyelomaWho this might be right forRefractory Multiple MyelomaRelapse Multiple MyelomaMultiple Myeloma Massachusetts General Hospital 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07524634What this trial is testingDose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) AmyloidosisWho this might be right forAmyloid Light-chain Amyloidosis Case Comprehensive Cancer Center 64
Testing effectiveness (Phase 2)Looking for participantsNCT07454382What this trial is testingElranatamab and Cyclophosphamide in People With Multiple MyelomaWho this might be right forMultiple Myeloma Memorial Sloan Kettering Cancer Center 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06931704What this trial is testingComparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Who this might be right forMultiple Myeloma Nantes University Hospital 176
Large-scale testing (Phase 3)Looking for participantsNCT05623020What this trial is testingLearn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantWho this might be right forMultiple Myeloma Pfizer 1,116
Not applicableActive Not RecruitingNCT06479954What this trial is testingNon Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.Who this might be right forRelapsed and Refractory Multiple Myeloma (RRMM) Pfizer 1
Large-scale testing (Phase 3)Looking for participantsNCT06152575What this trial is testingMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Who this might be right forMultiple Myeloma Pfizer 492
Not applicableStudy completedNCT06504524What this trial is testingCompare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USWho this might be right forMultiple Myeloma Pfizer 633